Protagonist Therapeutics, Inc. (PTGX) Cash Flow Statement

The relationship between net income and operating cash flow is highly erratic, with OCF/NI ranging from -12.94 to 1.04 across the last ten quarters. In 2026Q2, operating cash flow slightly exceeded net income, but in 2026Q1, a net income of $3.8M was accompanied by a -$48.9M operating cash outflow, indicating that non-cash items and working capital swings dominate. This suggests that reported earnings are not a reliable indicator of cash generation, as the company's cash flows are heavily influenced by the timing of milestone receipts and working capital changes.

The free cash flow trajectory is characterized by episodic spikes and troughs, with positive FCF only in quarters following major milestone payments, such as 2024Q2 ($268.6M) and 2026Q2 ($169.7M). Excluding these quarters, FCF is consistently negative, reflecting ongoing R&D investment without corresponding product revenue. This pattern suggests that the company's cash generation is not yet self-sustaining and remains dependent on external partnership milestones, which investors should monitor for sustainability.

CapEx has been consistently minimal, ranging from -$813K to $1.4M, and never exceeding 20% of revenue even in low-revenue quarters. This suggests that the company does not require significant fixed asset investment to operate, which is consistent with a biotech that outsources manufacturing and focuses on drug development. The low capital intensity implies that free cash flow is primarily driven by working capital and operating performance rather than capital expenditure cycles.

The working capital changes are highly volatile, with large positive and negative swings that correlate with milestone quarters. For instance, in 2024Q2, a $291.1M positive working capital change coincided with a $268.6M operating cash inflow, suggesting that collections from milestone payments were a major driver. Conversely, in 2024Q1, a -$243.3M working capital change offset a $207.3M net income, indicating that receivables or other current assets absorbed cash. This pattern suggests that the company's cash conversion cycle is heavily influenced by the timing of partnership payments, and investors should expect continued volatility.

The absence of dividends and buybacks, combined with consistent R&D spending, suggests that management is prioritizing internal investment over shareholder distributions. This is typical for a clinical-stage biotech, where cash is needed to fund ongoing trials and development. However, the lack of capital returns also means that shareholders are entirely reliant on stock price appreciation, which is tied to clinical and regulatory milestones.

The cumulative gap between net income and operating cash flow is positive, indicating that, on a cumulative basis, the company has converted more than 100% of its earnings into cash. However, this is largely due to the timing of milestone payments, which can cause cash to be received in different periods than the revenue is recognized. This divergence may not be sustainable if milestone payments become less frequent, and investors should monitor whether the company can achieve positive cash flow from recurring operations.